Friday, August 19, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



New Russian anti-Covid-19 drug successfully passes clinical trials

Rusia, Covid-19, fármaco, Globulin, nsayos, clínicos

New Russian anti-Covid-19 drug successfully passes clinical trials

Moscow, Dec 30 (Prensa Latina) The Russian state corporation Rostec reported this Thursday that its new drug COVID-Globulin, against the SARS-CoV-2 coronavirus, successfully passed clinical trials and received a certificate of permanent registration from the Health Ministry.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The course of studies of the drug based on blood plasma from people infected with the disease confirmed its effectiveness, safety and ability to neutralize the coronavirus, a company statement noted, referring to the new product of its subsidiary Natsimbio.

The application of COVID-Globulin helps the body to prevent the transition of the disease to a more severe form and to overcome the infection, it explained.

According to Rostec, the results of a placebo-controlled comparative investigation showed that seven out of 10 patients who received the new drug as part of a complex therapy for coping with Covid-19 had a reduced risk for the disease to worsen.

The data further evidenced that the product is most effective when used in the early stages of the condition and that in 70 percent of cases therapy with the drug prevented the development of complications arising in the context of the infection.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.